West Pharmaceutical Services, Inc. logo
WSTWest Pharmaceutical Services, Inc.

Debt to Assets Ratio: 7.69%

Is the debt to assets ratio high or low?

The debt to assets ratio of 7.69% is 13% below its 5-year average of 8.85%, near the low end of its 5-year range (7.25%–11.73%).

As of Saturday, June 27, 2026. 0.12% below its 12-month average of 7.70%.

Debt to Assets

WST Debt to Assets Ratio

7.69%

Reported quarterly debt to assets ratio; no daily interpolation.

-29.34% 5Y
WST Debt to Assets Ratio

WST Average Debt to Assets Ratio Chart

WST Debt to Assets Ratio

WST Current vs Average Debt to Assets Ratio Chart

WST Debt to Assets Ratio Metrics

DEBT TO ASSETS RATIO

7.69%

DEBT TO ASSETS RATIO AVG TTM

7.70%

DEBT TO ASSETS RATIO AVG 3Y

8.13%

DEBT TO ASSETS RATIO AVG 5Y

8.85%

DEBT TO ASSETS RATIO AVG 10Y

10.65%

DEBT TO ASSETS RATIO AVG 15Y

14.87%

DEBT TO ASSETS RATIO AVG 20Y

18.88%

CURRENT VS TTM AVG

-0.12%

CURRENT VS 3Y AVG

-5.36%

CURRENT VS 5Y AVG

-13.11%

CURRENT VS 10Y AVG

-27.78%

CURRENT VS 15Y AVG

-48.27%

CURRENT VS 20Y AVG

-59.25%

WST Competitors' Debt to Assets Ratio

NAMEMARKET CAPDEBT TO ASSETS RATIOTTM3Y5Y
West Pharmaceutical Services, Inc. (WST)$24.79B7.69%7.70%8.13%8.85%
Waters Corporation (WAT)vs ›$24.41B0.29%N/AN/AN/A
Mettler-Toledo International Inc. (MTD)vs ›$25.54B0.63%N/AN/AN/A
Quest Diagnostics Incorporated (DGX)vs ›$23.08B0.43%N/AN/AN/A
BioNTech SE (BNTX)vs ›$23.07B0.01%N/AN/AN/A
United Therapeutics Corporation (UTHR)vs ›$23.03B0.00%N/AN/AN/A
Moderna, Inc. (MRNA)vs ›$26.69B0.16%N/AN/AN/A
Incyte Corporation (INCY)vs ›$22.73B0.01%N/AN/AN/A
DexCom, Inc. (DXCM)vs ›$27.07B0.22%N/AN/AN/A
Labcorp Holdings Inc. (LH)vs ›$22.26B0.39%N/AN/AN/A

Leverage Ratios Comparison

Debt/Assets

7.7%

Debt/Equity

0.13

Current Ratio

3.02

Interest Coverage

1029.0x

Formula: Debt/Assets = Total Debt / Total Assets × 100

Debt/Assets vs Debt/Equity:

  • Debt/Assets: Shows % of assets funded by creditors (bounded 0-100%)
  • Debt/Equity: Shows debt relative to shareholder investment (can exceed 100%)
  • Both measure leverage but from different perspectives

Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.

Debt to Assets Ratio Formula & Definition

Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Debt to Assets Ratio FAQ

What is the debt to assets ratio for West Pharmaceutical Services, Inc. (WST)?
The debt to assets ratio for WST stock is 7.69%.
Is West Pharmaceutical Services, Inc.'s debt to assets ratio high or low?
The debt to assets ratio of 7.69% is 13% below its 5-year average of 8.85%, near the low end of its 5-year range (7.25%–11.73%).
What is the TTM average debt to assets ratio for West Pharmaceutical Services, Inc. (WST)?
The TTM average debt to assets ratio for WST stock is 7.70%.
What is the 3Y average debt to assets ratio for West Pharmaceutical Services, Inc. (WST)?
The 3Y average debt to assets ratio for WST stock is 8.13%.
What is the 5Y average debt to assets ratio for West Pharmaceutical Services, Inc. (WST)?
The 5Y average debt to assets ratio for WST stock is 8.85%.
What is the 10Y average debt to assets ratio for West Pharmaceutical Services, Inc. (WST)?
The 10Y average debt to assets ratio for WST stock is 10.65%.
What is the 15Y average debt to assets ratio for West Pharmaceutical Services, Inc. (WST)?
The 15Y average debt to assets ratio for WST stock is 14.87%.
What is the 20Y average debt to assets ratio for West Pharmaceutical Services, Inc. (WST)?
The 20Y average debt to assets ratio for WST stock is 18.88%.

WST Debt to Assets Ratio History

DATEDEBT TO ASSETS RATIO
2026-03-317.69%
2025-12-317.52%
2025-09-307.25%
2025-06-307.67%
2025-03-318.38%
2024-12-318.30%
2024-09-308.29%
2024-06-308.90%
2024-03-318.51%
2023-12-318.07%
2023-09-308.17%
2023-06-308.48%
2023-03-318.44%
2022-12-318.79%
2022-09-309.04%
2022-06-309.89%
2022-03-3110.05%
2021-12-319.82%
2021-09-3010.04%
2021-06-3010.89%
2021-03-3111.73%
2020-12-3111.66%
2020-09-3012.60%
2020-06-3013.66%
2020-03-3114.57%
2019-12-3114.06%
2019-09-3012.35%
2019-06-3012.84%
2019-03-3113.41%
2018-12-3112.31%
2018-09-3010.08%
2018-06-3010.48%
2018-03-3110.59%
2017-12-3110.58%
2017-09-3011.90%
2017-06-3012.45%
2017-03-3113.19%
2016-12-3113.32%
2016-09-3013.32%
2016-06-3013.57%
2016-03-3113.91%
2015-12-3117.59%
2015-09-3018.15%
2015-06-3019.64%
2015-03-3120.72%
2014-12-3120.08%
2014-09-3020.48%
2014-06-3021.21%
2014-03-3123.70%
2013-12-3122.34%
2013-09-3024.03%
2013-06-3024.48%
2013-03-3127.27%
2012-12-3126.31%
2012-09-3026.28%
2012-06-3026.35%
2012-03-3126.17%
2011-12-3124.97%
2011-09-3027.03%
2011-06-3026.39%
2011-03-3127.16%
2010-12-3127.69%
2010-09-3028.52%
2010-06-3029.23%
2010-03-3129.47%
2009-12-3129.87%
2009-09-3031.41%
2009-06-3032.05%
2009-03-3133.98%
2008-12-3133.03%
2008-09-3031.61%
2008-08-0531.77%
2008-03-3134.48%
2007-12-3133.32%
2007-09-3034.07%
2007-06-3033.67%
2007-03-3134.09%
2006-12-3125.74%
2006-09-3026.94%
2006-06-3029.41%
2006-03-3131.83%
2005-12-3134.12%
2005-09-3032.60%
2005-06-3034.85%
2005-03-3123.49%
2004-12-3124.41%
2004-09-3025.57%
2004-06-3025.55%
2004-03-3125.17%
2003-12-3128.06%
2003-09-3031.08%
2003-06-3031.65%
2003-03-3132.04%
2002-12-3132.60%
2002-09-3034.49%
2002-06-3035.29%

About West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.

Exton, PA
10,600 employees
Healthcare / Medical - Instruments & Supplies
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Eric Green